Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the number is still increasing rapidly. Herein, we present four critically ill patients with SARS-CoV-2 infection who received su...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bin, Liu, Shuyi, Tan, Tan, Huang, Wenhui, Dong, Yuhao, Chen, Luyan, Chen, Qiuying, Zhang, Lu, Zhong, Qingyang, Zhang, Xiaoping, Zou, Yujian, Zhang, Shuixing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195335/
https://www.ncbi.nlm.nih.gov/pubmed/32243945
http://dx.doi.org/10.1016/j.chest.2020.03.039
Descripción
Sumario:As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the number is still increasing rapidly. Herein, we present four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.

Ejemplares similares